← All organizations

Supernus Pharmaceuticals

For profitContributed to NMEWebsite ↗

Also known as: MDD US | Supernus Pharmaceuticals | Supernus Pharmaceuticals, Inc. | SUPERNUS PHARMS

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

First marketed drug

First NDA

Last known activity

Jan 1, 2026

Timeline

2000s

Jul 1, 2005
Supernus Pharmaceuticals— Founded

2010s

Sep 14, 2018
Biscayne Neurotherapeutics, Inc.— Acquired

2020s

Apr 2, 2021
viloxazine— Marketing Organization
Apr 2, 2021
viloxazine— NDA Secondary Org
Apr 2, 2021
viloxazine— NDA Organization
Oct 11, 2021
Adamas Pharmaceuticals, Inc.— Acquired
Apr 22, 2025
Sage Therapeutics— Acquired

Drugs by trial phase (19 distinct, 103 trials)

Phase 4 (2 own, 2 via acquisition)

Phase 3 (4 own, 3 via acquisition)

Phase 2 (1 own, 4 via acquisition)

Phase 1 (0 own, 2 via acquisition)

Other trials (0 own, 1 via acquisition)

tea

Indications

Studied for

Marketed drugs (6)

Subsidiaries (3 direct, 3 total across the full acquisition tree)

Recent trials (50)

NCT07226661Lead sponsorPhase 2Jan 1, 2026
NCT07125222CollaboratorPhase 2Sep 30, 2025
NCT07141329OfficialPhase 2Jul 30, 2025
NCT07141329Lead sponsorPhase 2Jul 30, 2025
NCT06798896OfficialPhase 2Dec 30, 2024
NCT06798896Lead sponsorPhase 2Dec 30, 2024
NCT06235905CollaboratorPhase 2Feb 15, 2024
NCT06185985Lead sponsorPhase 4Jan 31, 2024
NCT06259331Lead sponsorPhase 4May 23, 2023
NCT05518578Lead sponsorPhase 2Sep 30, 2022
NCT05518578Study directorPhase 2Sep 30, 2022
NCT05066672CollaboratorPhase 2Dec 31, 2021
NCT05097079Study chairPhase 3Nov 30, 2021
NCT05097079Lead sponsorPhase 3Nov 30, 2021
NCT05384977Lead sponsorPhase 1Nov 11, 2021

Details

Founded: Rockville, MD, US Jul 1, 2005
First NDA: Apr 2, 2021
Last known activity: Jan 1, 2026